Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 3, 2010, Pages 161-172

  Markart, Philipp ^a   Nass, Robert ^a   Ruppert, Clemens ^a   Hundack, Lukas ^a   Wygrecka, Malgorzata ^a   Korfei, Martina ^a   Boedeker, Rolf H ^a   Staehler, Gerd ^b   Kroll, Hartmut ^c   Scheuch, Gerhard ^d   Seeger, Werner ^a   Guenther, Andreas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Loewenstein Hospital   (Germany)

^c Institute for Transfusion Medicine Dessau   (Germany)

^d Activaero GmbH   (Germany)

Author keywords

Anticoagulant agents; Clinical trial; Inhaled therapy; Interstitial lung diseases; IPF; Lung fibrosis; Nebulizer

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CARBON MONOXIDE; HEPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; GAS EXCHANGE; HEMOPTYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LONG TERM CARE; LUNG ALVEOLUS; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TOXICITY; MALE; OXYGEN TENSION; PARTIAL THROMBOPLASTIN TIME; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; THROMBOPLASTIN TIME; TOTAL LUNG CAPACITY; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; HALF LIFE TIME; IDIOPATHIC PULMONARY FIBROSIS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTICOAGULANTS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; HALF-LIFE; HEPARIN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TIME FACTORS; YOUNG ADULT;

EID: 77953933778     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0780     Document Type: Article

References (50)

1. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
2. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, and Wells AU: Fibrotic idiopathic interstitial pneumonia. The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531-537.
3. Kotani I, Sato A, Hayakaya H, Urano T, Takada Y, and Takada A: Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res. 1995;77:493-504.
4. Guenther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, and Seeger W: Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000;83:853-860.
5. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, and Takada A: Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med. 1997;156:631-636.
6. Kuhn C 3rd, Boldt J, King TE, Crouch E, Vartio T, and McDonald JA: An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140:1693-1703.
7. Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, and Laurent GJ: Thrombin stimulates fibroblast procollagen production via proteolytic activation of proteaseactivated receptor 1. Biochem J. 1998;333:121-127.
8. Blanc-Brude OP, Archer F, Leoni P, Derian C, Bolsover S, Laurent GJ, and Chambers RC: Factor Xa stimulates fibroblast procollagen production proliferation and calcium signaling via PAR1 activation. Exp Cell Res. 2005;304:16-27.
9. Bogatkevich GS, Tourkina E, Silver RM, and Ludwicka-Bradley A: Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem. 2001;276:45184-45192.
10. Chambers R, Leoni P, Blanc-Brude O, Wembridge D, and Laurent GJ: Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem. 2000;275: 35584-35591.
11. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, and Metcalfe JC: Release and activation of platelet latent TGFbeta in blood clots during dissolution with plasmin. Nat Med. 1995;1:932-937.
12. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis. 1989;140:513-524. (Pubitemid 19218368)
13. Seeger W, Elssner A, Guenther A, Kraemer HJ, and Kalinowski HO: Lung surfactant phospholipids associate with polymerizing fibrin-loss of surfactant activity. Am J Respir Cell Mol Biol. 1993;9:213-220.
14. Matzner Y, Marx G, Drexler R, and Eldor A: The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost. 1984;52:134-137.
15. Sasaki M, Kashima M, Ito T, Watanabe A, Sano M, Kagaya M, Shioya T, and Miura M: Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity. Mediators Inflamm. 2000;9:85-91.
16. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, and Taguchi O: Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med. 2001;163:1660-1668.
17. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, Laurent GJ, and Chambers RC: Direct thrombin inhibition reduces lung collagen accumulation and connective tissue growth factor mRNA levels in bleomycininduced pulmonary fibrosis.AmJ Pathol. 2001;159:1383-1395.
18. Piguet PF, Van GY, and Guo J: Heparin attenuates bleomycin but not silica-induced pulmonary fibrosis in mice: possible relationship with involvement of myofibroblasts in bleomycin and fibroblasts in silica-induced fibrosis. Int J Exp Pathol. 1996;77:155-161.
19. Guenther A, Luebcke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quantz K, Ermert L, Grimminger F, and Seeger W: Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med. 2003;168:1358-1365.
20. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, and Sasaki H: Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-1482.
21. Brand P, Beckmann H, Maas Enriquez M, Meyer T, Muellinger B, Sommerer K, Weber N, Weuthen T, and Scheuch G: Peripheral deposition of a1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003;22:263-267.
22. Scheuch G, Brand P, Meyer T, Herpich C, Muellinger B, Brom J, Weidinger G, Kohlhaeufl M, Haeussinger K, Spannagl M, Schramm W, and Siekmeier R: Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. J Physiol Pharmacol. 2007;58:603-614.
23. American Thoracic Society=European Respiratory Society: International multidisciplinary consensus classification of the Idiopathic Interstitial Pneumonias. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2002;165:277-304.
24. Baumgartner KB, Sarnet J, Stidley CA, Colby TV, and Waldron JA: Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155: 242-248.
25. Hubbard R, Lewis S, Richards K, Johnston I, and Britton J: Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996;347: 284-289. (Pubitemid 26041039)
26. Iwai K, Mori T, Yamada N, Yamaguchi M, and Hosoda Y: Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994;150:670-675.
27. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stä hler G, Leconte I, Roux S, and Raghu G: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81.
28. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M, and the IFIGENIA Study Group: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
29. R Development Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2006.
30. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, and Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med. 1999;130:800-809.
31. Quinlan DJ,McQuillan A, and EikelboomJW: Low-molecularweight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A Meta-Analysis of Randomized Controlled Trials. Ann Intern Med. 2004;140:175-183.
32. Bendstrup KE, Chambers CB, Jensen JI, and Newhouse MT: Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med. 1999; 160:1653-1658.
33. Bendstrup KE, Gram J, and Jensen JI: Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J. 2002;19:606-610.
34. Hellgren M, Högnevik K, and Blombäck M: Heparin aerosol effect on blood coagulation and pulmonary function. Thromb Res. 1981;21:493-502.
35. Jaques LB, Mahadoo J, and Kavanagh LW: Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet. 1976;2:1157-1161.
36. Köhler D. Aerosolized heparin. J Aerosol Med. 1994;7: 307-314.
37. Diamant Z, Timmers MC, van der Veen H, Page CP, van der Meer FJ, and Sterk PJ: Effect of inhaled heparin on allergeninduced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med. 1996;153: 1790-1795.
38. Ahmed T, Garrigo J, and Danta I: Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med. 1993;329:90-95.
39. Bardana EJ Jr, Edwards MJ, and Pirofsky B: Heparin as treatment for bronchospasm of asthma. Ann Allergy. 1969;27:108-113.
40. Ahmed T, Gonzalez BJ, and Danta I. Prevention of exerciseinduced bronchoconstriction by inhaled low-molecularweight heparin. Am J Respir Crit Care Med. 1999;160: 576-581.
41. Bendstrup KE and Jensen JI: Inhaled heparin is effective in exacerbations of asthma. Respir Med 2000;94:174-175.
42. Youngchaiyud P, Kettel LJ, and Cugell DW: The effect of heparin aerosols on airway conductance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1969;99:449-452.
43. Serisier DJ, Shute JK, Hockey PM, Higgins B, Conway J, and Carroll MP. Inhaled heparin in cystic fibrosis. Eur Respir J. 2006;27:354-358.
44. Ledson M, Gallagher M, Hart CA, and Walshaw M: Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. Eur Respir J. 2001;17:36-38.
45. Dixon B, Santamaria JD, and Campbell DJ: A phase 1 trial of nebulised heparin in acute lung injury. Crit Care. 2008; 12:R64.
46. Qi Y, Zhao G, Liu D, Shriver Z, Sundaram M, Sengupta S, Venkataraman G, Langer R, and Sasisekharan R: Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc Natl Acad Sci USA. 2004;101:9867-9872.
47. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, and Traber DL: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock. 2002;18:236-241.
48. Enkhbaatar P, Cox RA, Traber LD, Westphal M, Aimalohi E, Morita N, Prough DS, Herndon DN, and Traber DL: Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med. 2007;35:2805-2810. (Pubitemid 350175779)
49. Enkhbaatar P, Esechie A, Wang J, Cox RA, Nakano Y, Hamahata A, Lange M, Traber LD, Prough DS, Herndon DN, and Traber DL: Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation. Clin Sci (Lond). 2008;114:321-329.
50. Kinder BW, Collard HR, and King TE: Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 2006;130: 302-303.